Oregon Rural Practice-based Research Network, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Rd., Mail Code L222, Portland, Oregon, 97239, USA.
OCHIN, Inc, Portland, USA.
BMC Health Serv Res. 2022 Feb 15;22(1):204. doi: 10.1186/s12913-022-07576-4.
Colorectal cancer (CRC) screening can improve health outcomes, but screening rates remain low across the US. Mailed fecal immunochemical tests (FIT) are an effective way to increase CRC screening rates, but is still underutilized. In particular, cost of FIT has not been explored in relation to practice characteristics, FIT selection, and screening outreach approaches.
We administered a cross-sectional survey drawing from prior validated measures to 252 primary care practices to assess characteristics and context that could affect the implementation of direct mail fecal testing programs, including the cost, source of test, and types of FIT used. We analyzed the range of costs for the tests, and identified practice and test procurement factors. We examined the distributions of practice characteristics for FIT use and costs answers using the non-parametric Wilcoxon rank-sum test. We used Pearson's chi-squared test of association and interpreted a low p-value (e.g. < 0.05) as evidence of association between a given practice characteristic and knowing the cost of FIT or fecal occult blood test (FOBT).
Among the 84 viable practice survey responses, more than 10 different types of FIT/FOBTs were in use; 76% of practices used one of the five most common FIT types. Only 40 practices (48%) provided information on FIT costs. Thirteen (32%) of these practices received the tests for free while 27 (68%) paid for their tests; median reported cost of a FIT was $3.04, with a range from $0.83 to $6.41 per test. Costs were not statistically significantly different by FIT type. However, practices who received FITs from manufacturer's vendors were more likely to know the cost (p = 0.0002) and, if known, report a higher cost (p = 0.0002).
Our findings indicate that most practices without lab or health system supplied FITs are spending more to procure tests. Cost of FIT may impact the willingness of practices to distribute FITs through population outreach strategies, such as mailed FIT. Differences in the ability to obtain FIT tests in a cost-effective manner could have consequences for implementation of outreach programs that address colorectal cancer screening disparities in primary care practices.
结直肠癌(CRC)筛查可以改善健康结果,但美国的筛查率仍然很低。邮寄粪便免疫化学检测(FIT)是提高 CRC 筛查率的有效方法,但仍未得到充分利用。特别是,FIT 的成本与实践特征、FIT 选择和筛查外展方法之间的关系尚未得到探讨。
我们对 252 家初级保健机构进行了横断面调查,以评估可能影响直接邮寄粪便检测计划实施的特征和背景,包括检测成本、检测来源和使用的 FIT 类型。我们分析了检测成本的范围,并确定了实践和检测采购因素。我们使用非参数 Wilcoxon 秩和检验分析了 FIT 使用和成本答案的分布。我们使用 Pearson 卡方检验关联,低 p 值(例如 <0.05)表示给定实践特征与了解 FIT 或粪便潜血试验(FOBT)成本之间存在关联的证据。
在 84 份可行的实践调查回复中,使用了 10 多种不同类型的 FIT/FOBT;76%的实践使用了最常见的 FIT 类型中的一种。只有 40 家实践(48%)提供了 FIT 成本信息。其中 13 家(32%)免费获得检测,27 家(68%)付费;报告的 FIT 平均检测成本为 3.04 美元,检测费用范围为 0.83 美元至 6.41 美元。FIT 类型之间的成本没有统计学上的显著差异。然而,从制造商供应商处获得 FIT 的实践更有可能了解成本(p=0.0002),并且如果知道,报告的成本更高(p=0.0002)。
我们的研究结果表明,大多数没有实验室或卫生系统提供 FIT 的实践都在花费更多的资金来采购检测。FIT 的成本可能会影响实践通过人群外展策略(例如邮寄 FIT)分发 FIT 的意愿。以具有成本效益的方式获得 FIT 检测的能力差异可能会对初级保健实践中结直肠癌筛查差异的外展计划的实施产生影响。